MX393588B - Formulaciones muco-adhesivas de liberacion controlada de levodopa y/o esteres de levodopa y sus usos - Google Patents
Formulaciones muco-adhesivas de liberacion controlada de levodopa y/o esteres de levodopa y sus usosInfo
- Publication number
- MX393588B MX393588B MX2019013171A MX2019013171A MX393588B MX 393588 B MX393588 B MX 393588B MX 2019013171 A MX2019013171 A MX 2019013171A MX 2019013171 A MX2019013171 A MX 2019013171A MX 393588 B MX393588 B MX 393588B
- Authority
- MX
- Mexico
- Prior art keywords
- levodopa
- controlled release
- muco
- adhesive
- esters
- Prior art date
Links
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title abstract 4
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title abstract 4
- 229960004502 levodopa Drugs 0.000 title abstract 4
- 238000013270 controlled release Methods 0.000 title abstract 3
- 150000002148 esters Chemical class 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000003232 mucoadhesive effect Effects 0.000 title abstract 2
- 229940123736 Decarboxylase inhibitor Drugs 0.000 abstract 1
- 239000002998 adhesive polymer Substances 0.000 abstract 1
- 239000003954 decarboxylase inhibitor Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Adhesives Or Adhesive Processes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361887762P | 2013-10-07 | 2013-10-07 | |
| PCT/US2014/059554 WO2015054302A1 (en) | 2013-10-07 | 2014-10-07 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019013171A MX2019013171A (es) | 2019-12-18 |
| MX393588B true MX393588B (es) | 2025-03-04 |
Family
ID=52813592
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019013171A MX393588B (es) | 2013-10-07 | 2014-10-07 | Formulaciones muco-adhesivas de liberacion controlada de levodopa y/o esteres de levodopa y sus usos |
| MX2016004455A MX369315B (es) | 2013-10-07 | 2014-10-07 | Formulaciones muco-adhesivas de liberacion controlada de levodopa y/o esteres de levodopa y sus usos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016004455A MX369315B (es) | 2013-10-07 | 2014-10-07 | Formulaciones muco-adhesivas de liberacion controlada de levodopa y/o esteres de levodopa y sus usos. |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US10098845B2 (https=) |
| EP (2) | EP3054929B1 (https=) |
| JP (3) | JP6506271B2 (https=) |
| KR (2) | KR102266091B1 (https=) |
| CN (1) | CN105658211A (https=) |
| AU (3) | AU2014332024B2 (https=) |
| CA (1) | CA2926082C (https=) |
| ES (1) | ES2823000T3 (https=) |
| IL (2) | IL244920B (https=) |
| MX (2) | MX393588B (https=) |
| PL (1) | PL3054929T3 (https=) |
| WO (1) | WO2015054302A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8377474B2 (en) | 2007-12-28 | 2013-02-19 | Impax Laboratories, Inc. | Controlled release formulations of levodopa and uses thereof |
| AU2014332024B2 (en) | 2013-10-07 | 2019-09-26 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
| US10987313B2 (en) | 2013-10-07 | 2021-04-27 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
| US11229600B2 (en) * | 2014-09-24 | 2022-01-25 | Vital Beverages Global Inc. | Compositions and methods for selective GI tract delivery |
| CA2902911C (en) | 2014-10-31 | 2017-06-27 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
| US11759417B2 (en) | 2018-02-28 | 2023-09-19 | Shanghai Wd Pharmaceutical Co., Ltd | Pharmaceutical composition and preparation method therefor and use thereof |
| EP3797818B1 (en) * | 2018-05-23 | 2023-01-18 | Shanghai WD Pharmaceutical Co., Ltd | Controlled-release system of active pharmaceutical ingredient and preparation method therefor |
| US11911513B2 (en) | 2018-05-23 | 2024-02-27 | Shanghai Wd Pharmaceutical Co., Ltd | Controlled-release system of active pharmaceutical ingredient and preparation method therefor |
| US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
| CN110075345B (zh) * | 2019-04-01 | 2021-12-10 | 杭州英健生物科技有限公司 | 适用于胃窥镜喷涂到胃损伤黏膜表面的双组分自粘性胃黏膜保护胶及其应用 |
| US12161755B2 (en) | 2020-11-14 | 2024-12-10 | Regents Of The University Of Minnesota | Sustained release device for treatment of Parkinson's disease and other disorders |
| CN116887866A (zh) | 2020-12-03 | 2023-10-13 | 巴特尔纪念研究院 | 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法 |
| US11986449B2 (en) | 2020-12-22 | 2024-05-21 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
| EP4267113A4 (en) * | 2020-12-22 | 2025-02-12 | Amneal Pharmaceuticals LLC | LEVODOPA DOSING SCHEME |
| CN114762684B (zh) * | 2021-01-14 | 2023-11-21 | 华益泰康药业股份有限公司 | 一种治疗帕金森的缓释胶囊及其制备方法 |
| WO2022216977A1 (en) | 2021-04-07 | 2022-10-13 | Batelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
| JPWO2024024865A1 (https=) * | 2022-07-28 | 2024-02-01 | ||
| CN117919217A (zh) * | 2022-10-14 | 2024-04-26 | 浙江华海药业股份有限公司 | 一种用于治疗帕金森病的药物组合物及其制备方法 |
| KR102903389B1 (ko) * | 2022-11-30 | 2025-12-23 | 주식회사한국파마 | 신경퇴행성 질환 예방 또는 치료용 필름코팅정제 |
| US11931224B1 (en) * | 2022-12-19 | 2024-03-19 | Robert Parker | Tooth pod |
| CN116808001A (zh) * | 2023-05-04 | 2023-09-29 | 上海信谊万象药业股份有限公司 | 一种多巴丝肼肠溶微丸胶囊及其制备工艺 |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| US12441996B2 (en) | 2023-12-08 | 2025-10-14 | Battelle Memorial Institute | Use of DNA origami nanostructures for molecular information based data storage systems |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3891696A (en) | 1973-11-02 | 1975-06-24 | Interx Research Corp | Novel, transient pro-drug forms of l-dopa |
| DE2513940A1 (de) | 1975-03-29 | 1976-10-14 | Merck Patent Gmbh | Pharmazeutische zubereitung |
| US4077407A (en) | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
| FR2470599A1 (fr) | 1979-12-07 | 1981-06-12 | Panoz Donald | Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus |
| DE3000979A1 (de) | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
| DE3124090A1 (de) | 1981-06-19 | 1983-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale dipyridamolformen |
| DE3126703A1 (de) | 1981-07-07 | 1983-01-27 | Dr. Karl Thomae Gmbh, 7950 Biberach | Bromhexin-retardform und verfahren zu ihrer herstellung |
| US4424235A (en) | 1981-09-14 | 1984-01-03 | Hoffmann-La Roche Inc. | Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor |
| US5188840A (en) | 1985-09-26 | 1993-02-23 | Chugai Seiyaku Kabushiki Kaisha | Slow-release pharmaceutical agent |
| IT1188212B (it) | 1985-12-20 | 1988-01-07 | Paolo Colombo | Sistema per il rilascio a velocita' controllata di sostanze attive |
| US4849227A (en) | 1986-03-21 | 1989-07-18 | Eurasiam Laboratories, Inc. | Pharmaceutical compositions |
| ES2042520T3 (es) | 1986-06-10 | 1993-12-16 | Chiesi Farma Spa | Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo. |
| NZ220599A (en) | 1986-06-16 | 1990-10-26 | Merck & Co Inc | Controlled release oral dosage formulation of carbidopa and levodopa |
| ZA889189B (en) | 1986-06-16 | 1989-08-30 | Merck & Co Inc | Controlled release combination of carbidopa/levodopa |
| US4832957A (en) | 1987-12-11 | 1989-05-23 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| YU213587A (en) | 1986-11-28 | 1989-06-30 | Orion Yhtymae Oy | Process for obtaining new pharmacologic active cateholic derivatives |
| FI864875A0 (fi) | 1986-11-28 | 1986-11-28 | Orion Yhtymae Oy | Nya farmakologiskt aktiva foereningar, dessa innehaollande kompositioner samt foerfarande och mellanprodukter foer anvaendning vid framstaellning av dessa. |
| US5283352A (en) | 1986-11-28 | 1994-02-01 | Orion-Yhtyma Oy | Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same |
| US4855326A (en) | 1987-04-20 | 1989-08-08 | Fuisz Pharmaceutical Ltd. | Rapidly dissoluble medicinal dosage unit and method of manufacture |
| JP2782691B2 (ja) | 1987-09-29 | 1998-08-06 | ワーナー−ランバート・コンパニー | 腸溶製剤の安定化 |
| US4938968A (en) | 1988-07-26 | 1990-07-03 | Norjec Development Associates, Inc. | Controlled release indomethacin |
| IT1229856B (it) | 1989-04-20 | 1991-09-13 | Recordati Chem Pharm | Compresse a rilascio controllato contenenti flavossato. |
| GB2238047B (en) | 1989-11-03 | 1993-02-10 | Orion Yhtymae Oy | Stable polymorphic form of (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide and the process for its preparation |
| IE66933B1 (en) | 1990-01-15 | 1996-02-07 | Elan Corp Plc | Controlled absorption naproxen formulation for once-daily administration |
| US5624960A (en) | 1991-01-23 | 1997-04-29 | Isis Pharma Gmbh | Orally administrable drugs for the treatment of central dopamine deficiency conditions |
| DE4101873C2 (de) | 1991-01-23 | 1993-12-09 | Isis Pharma Gmbh | Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände |
| US5388857A (en) | 1992-08-27 | 1995-02-14 | Badger Equipment Company | Operator controlled vehicle stabilizer |
| IT1255522B (it) | 1992-09-24 | 1995-11-09 | Ubaldo Conte | Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita' |
| GB9309749D0 (en) | 1993-05-12 | 1993-06-23 | Boots Co Plc | Therapeutic agents |
| IT1264517B1 (it) | 1993-05-31 | 1996-09-24 | Ekita Investments Nv | Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati |
| IT1264696B1 (it) | 1993-07-09 | 1996-10-04 | Applied Pharma Res | Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata |
| EP0711166A1 (en) | 1993-07-22 | 1996-05-15 | Warner-Lambert Company | Controlled release tacrine drug delivery systems and methods for preparing same |
| IT1266565B1 (it) | 1993-07-22 | 1997-01-09 | Ct Lab Farm Srl | Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico. |
| US6183778B1 (en) | 1993-09-21 | 2001-02-06 | Jagotec Ag | Pharmaceutical tablet capable of liberating one or more drugs at different release rates |
| SG80553A1 (en) | 1995-07-20 | 2001-05-22 | Tanabe Seiyaku Co | Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract |
| US5840756A (en) | 1995-07-21 | 1998-11-24 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition of L-DOPA ester |
| AUPN605795A0 (en) | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
| IT1282576B1 (it) | 1996-02-06 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili |
| IT1282650B1 (it) | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
| US5773031A (en) | 1996-02-27 | 1998-06-30 | L. Perrigo Company | Acetaminophen sustained-release formulation |
| IT1289160B1 (it) | 1997-01-08 | 1998-09-29 | Jagotec Ag | Compressa farmaceutica completamente rivestita per il rilascio controllato di principi attivi che presentano problemi di |
| US6756056B2 (en) | 1997-04-08 | 2004-06-29 | Alan A. Rubin | Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa |
| US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
| IT1293764B1 (it) | 1997-07-23 | 1999-03-10 | Chiesi Farma Spa | Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua |
| IT1295271B1 (it) * | 1997-10-03 | 1999-05-04 | Chiesi Farma Spa | Monolita contenente uno o piu'farmaci costituito da tre strati a meccanismo di rilascio differenziato |
| US6372254B1 (en) | 1998-04-02 | 2002-04-16 | Impax Pharmaceuticals Inc. | Press coated, pulsatile drug delivery system suitable for oral administration |
| US5945424A (en) | 1998-07-31 | 1999-08-31 | G & H Associates, Inc. | Treatment of periodic limb movement syndrome |
| WO2000015197A1 (en) | 1998-09-14 | 2000-03-23 | Rubin Alan A | Improvement in treatment of parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa |
| US6602521B1 (en) | 1998-09-29 | 2003-08-05 | Impax Pharmaceuticals, Inc. | Multiplex drug delivery system suitable for oral administration |
| EP1126826B3 (en) | 1998-11-02 | 2019-05-15 | Alkermes Pharma Ireland Limited | Multiparticulate modified release composition of methylphenidate |
| CA2350304A1 (en) | 1998-11-10 | 2000-05-18 | Teva Pharmaceutical Industries, Ltd. | Dispersible compositions containing l-dopa ethyl ester |
| WO2000035419A2 (en) | 1998-12-17 | 2000-06-22 | Alza Corporation | Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings |
| FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| NZ518309A (en) | 1999-11-11 | 2003-05-30 | Pharmacia Ab | Controlled release tolterodine formulation that releases not less than 80% of the active compound in under 18 hours |
| US6627223B2 (en) | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
| US6372252B1 (en) | 2000-04-28 | 2002-04-16 | Adams Laboratories, Inc. | Guaifenesin sustained release formulation and tablets |
| JP2004501190A (ja) | 2000-06-23 | 2004-01-15 | テバ ファーマシューティカル インダストリーズ リミティド | 治療薬の胃部保留および制御された放出のための急速膨張する組成物とその組成物を含む剤形 |
| US6733781B2 (en) | 2000-12-06 | 2004-05-11 | Wyeth | Fast dissolving tablet |
| US6531153B2 (en) | 2001-05-29 | 2003-03-11 | Drugtech Corporation | Composition with sustained release of levodopa and carbidopa |
| US20040028613A1 (en) | 2001-06-25 | 2004-02-12 | Nastech Pharmaceutical Company Inc | Dopamine agonist formulations for enhanced central nervous system delivery |
| IL159812A0 (en) * | 2001-07-12 | 2004-06-20 | Teva Pharma | Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester in a controlled release core |
| IL159813A0 (en) | 2001-07-12 | 2004-06-20 | Teva Pharma | Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core |
| US6723348B2 (en) | 2001-11-16 | 2004-04-20 | Ethypharm | Orodispersible tablets containing fexofenadine |
| US6811794B2 (en) | 2001-12-20 | 2004-11-02 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
| US7094427B2 (en) | 2002-05-29 | 2006-08-22 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
| US20040166159A1 (en) | 2002-05-29 | 2004-08-26 | Chien-Hsuan Han | Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa |
| US20030224045A1 (en) | 2002-05-29 | 2003-12-04 | Chien-Hsuan Han | Combination immediate release sustained release levodopa/carbidopa dosage forms |
| US20050147670A1 (en) | 2002-05-29 | 2005-07-07 | Impax Laboratories Inc. | Oral disintegrating dosage forms |
| US20060013875A1 (en) | 2002-05-29 | 2006-01-19 | Impax Laboratories, Inc. | Combination immediate release controlled release levodopa/carbidopa dosage forms |
| CA2514879C (en) | 2003-01-03 | 2014-09-16 | Shire Laboratories Inc. | Two or more enteric materials to regulate drug release |
| CA2520660C (en) | 2003-03-28 | 2013-08-20 | Sigmoid Biotechnologies Limited | Solid oral dosage form containing seamless microcapsules |
| ATE341857T1 (de) * | 2003-06-04 | 2006-10-15 | Koninkl Philips Electronics Nv | Bitdetektionsanordnung und vorrichtung zur wiedergabe von informationen |
| US20050070608A1 (en) | 2003-08-29 | 2005-03-31 | Julius Remenar | Pharmaceutical compositions and method of using levodopa and carbidopa |
| US8815950B2 (en) | 2003-08-29 | 2014-08-26 | Janssen Biotech, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| US8007827B2 (en) | 2004-04-02 | 2011-08-30 | Impax Laboratories, Inc. | Pharmaceutical dosage forms having immediate release and/or controlled release properties |
| WO2005099678A1 (en) | 2004-04-06 | 2005-10-27 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| US8015148B2 (en) | 2004-06-30 | 2011-09-06 | International Business Machines Corporation | Selective profiler for use with transaction processing applications |
| JP2006018748A (ja) * | 2004-07-05 | 2006-01-19 | Canon Inc | 情報処理装置及びその制御方法、並びにコンピュータプログラム及びコンピュータ可読記憶媒体 |
| US20060045865A1 (en) * | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
| JP2008516893A (ja) | 2004-08-27 | 2008-05-22 | スフェリックス，インク． | 多層錠剤および生体接着性剤形 |
| US20070082048A1 (en) * | 2005-06-08 | 2007-04-12 | Ronald Warner | Sleep aid formulations |
| WO2007002518A1 (en) | 2005-06-23 | 2007-01-04 | Spherics, Inc. | Delayed release or extended-delayed release dosage forms of pramipexole |
| AU2006261893A1 (en) | 2005-06-23 | 2007-01-04 | Combinatorx, Incorporated | Improved dosage forms for movement disorder treatment |
| US20070275060A1 (en) | 2005-08-05 | 2007-11-29 | Osmotica Costa Rica Sociedad Anonima | Extended release solid pharmaceutical composition containing carbidopa and levodopa |
| KR20080037732A (ko) | 2005-08-22 | 2008-04-30 | 노파르티스 아게 | ｐＨ-의존성 약물, ｐＨ 개질제 및 지연제를 포함하는제약학적 조성물 |
| FR2891459B1 (fr) | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
| RU2428176C2 (ru) | 2006-01-27 | 2011-09-10 | Юранд, Инк. | Системы доставки лекарственного средства, содержащие слабоосновные лекарственные средства и органические кислоты |
| CN103211779B (zh) | 2006-01-27 | 2016-03-16 | 阿代尔制药股份有限公司 | 包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统 |
| US8637080B2 (en) * | 2007-06-28 | 2014-01-28 | Osmotica Kereskedelmi és Szolgáltató, KFT | Rupturing controlled release device comprising a subcoat |
| US8377474B2 (en) * | 2007-12-28 | 2013-02-19 | Impax Laboratories, Inc. | Controlled release formulations of levodopa and uses thereof |
| AU2009240793B2 (en) * | 2008-04-24 | 2014-07-10 | Indice Pty Ltd | Power control |
| US20100331244A1 (en) | 2009-06-01 | 2010-12-30 | The University Of Tokyo | Pharmaceutical composition, food or drink, and methods related thereto |
| WO2011056240A2 (en) * | 2009-11-09 | 2011-05-12 | Xenoport, Inc. | Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use |
| US20140037614A1 (en) | 2011-04-05 | 2014-02-06 | Knut Pettersson | Therapeutic and prophylactic methods, uses and compositions comprising anexin a5 |
| EP2508174A1 (en) * | 2011-04-06 | 2012-10-10 | Ljiljana Sovic Brkicic | Pharmaceutical composition |
| US20130195973A1 (en) | 2012-01-30 | 2013-08-01 | Ranbaxy Laboratories Limited | Extended release pharmaceutical dosage forms of carbidopa and levodopa and process of preparation thereof |
| AU2014332024B2 (en) * | 2013-10-07 | 2019-09-26 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
-
2014
- 2014-10-07 AU AU2014332024A patent/AU2014332024B2/en active Active
- 2014-10-07 CN CN201480055451.3A patent/CN105658211A/zh active Pending
- 2014-10-07 US US15/027,654 patent/US10098845B2/en active Active
- 2014-10-07 KR KR1020167011939A patent/KR102266091B1/ko active Active
- 2014-10-07 JP JP2016521328A patent/JP6506271B2/ja active Active
- 2014-10-07 EP EP14851749.3A patent/EP3054929B1/en not_active Revoked
- 2014-10-07 WO PCT/US2014/059554 patent/WO2015054302A1/en not_active Ceased
- 2014-10-07 ES ES14851749T patent/ES2823000T3/es active Active
- 2014-10-07 CA CA2926082A patent/CA2926082C/en active Active
- 2014-10-07 MX MX2019013171A patent/MX393588B/es unknown
- 2014-10-07 MX MX2016004455A patent/MX369315B/es active IP Right Grant
- 2014-10-07 KR KR1020217017860A patent/KR102356190B1/ko active Active
- 2014-10-07 PL PL14851749T patent/PL3054929T3/pl unknown
- 2014-10-07 EP EP20186769.4A patent/EP3782614A1/en active Pending
-
2016
- 2016-04-05 IL IL244920A patent/IL244920B/en active IP Right Grant
- 2016-04-06 US US15/092,086 patent/US10292935B2/en active Active
-
2019
- 2019-03-21 US US16/360,936 patent/US10688058B2/en active Active
- 2019-03-27 JP JP2019059915A patent/JP6898375B2/ja active Active
- 2019-12-23 AU AU2019284060A patent/AU2019284060B2/en active Active
-
2020
- 2020-02-19 IL IL272772A patent/IL272772B/en unknown
- 2020-05-01 US US16/864,323 patent/US10973769B2/en active Active
-
2021
- 2021-06-09 JP JP2021096298A patent/JP2021127349A/ja active Pending
- 2021-12-06 AU AU2021282393A patent/AU2021282393B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX393588B (es) | Formulaciones muco-adhesivas de liberacion controlada de levodopa y/o esteres de levodopa y sus usos | |
| EP3188725A4 (en) | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof | |
| WO2012003367A3 (en) | Method for delivering an active agent | |
| TWI561593B (en) | Anti-corrosive coating composition, anti-corrosive coating film and anti-corrosive method of base member | |
| EP3371152A4 (en) | COMPOSITIONS WITH AN INHIBITOR OF LYSINE-SPECIFIC DEMETHYLASE-1 | |
| EP3179858A4 (en) | Forms and compositions of an erk inhibitor | |
| IL277683A (en) | Mono-salts of 6-aminoquinoline and their uses | |
| IL223865B (en) | Calcium salts of dihydroortate dehydrogenase inhibitors, preparations containing them and their uses | |
| PH12016501034A1 (en) | Oral care compositions and methods | |
| EP3596085A4 (en) | DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES | |
| PL3426243T3 (pl) | Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania | |
| PH12015502154A1 (en) | Composition for oral cavity | |
| MX354241B (es) | Composiciones para cuidado oral y metodos. | |
| MX2021001790A (es) | Composiciones solidas de trigliceridos y usos de estas. | |
| MX358871B (es) | Composiciones y metodos para el cuidado oral. | |
| MX2016008211A (es) | Composiciones para cuidado oral y metodos. | |
| UY34455A (es) | Formulación oral compleja que comprende ácido graso omega 3 e inhibidor de la hmg-coa reductasa con estabilidad mejorada | |
| CL2016000179A1 (es) | Formulación de combinación que contiene metformina de liberación prolongada e inhibidor de la hmg-coa reductasa de liberación inmediata. | |
| MX2016000797A (es) | Imidazolcarboxamidas y su uso como inhibidores de amida de acidos grasos hidrolasa (faah). | |
| MX2016008234A (es) | Composiciones para cuidado oral y metodos. | |
| MX356027B (es) | Composiciones para cuidado oral y metodos. | |
| NZ628867A (en) | Pharmaceutical formulation containing flupirtine | |
| HK40025148A (en) | Formulations of homotaurines and salts thereof | |
| CR20130631A (es) | Composiciones sòlidas |